Dual inhibition of these targets would be a significant therapeutic opportunity, and it would be interesting to observe the molecular mechanism and whether there are other compensatory mechanisms in HIF1α inhibitor-resistant PCa. The gene discussed is HIF1A; the disease is posterior cortical atrophy.